- Investing Ideas
- /
- Swiss Pharmaceuticals & Biotech Strong Balance Sheet Stocks
Swiss Pharmaceuticals & Biotech Strong Balance Sheet Stocks
Results
15
Strong Balance Sheet Stocks: companies with a Health score of at least 4, ordered by Health score.
15 companies
Bachem Holding
Market Cap: CHF 3.8b
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
BANB
CHF 50.65
7D
-1.7%
1Y
-38.8%
Kuros Biosciences
Market Cap: CHF 983.1m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
KURN
CHF 25.62
7D
2.5%
1Y
212.4%
Molecular Partners
Market Cap: CHF 122.8m
A clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.
MOLN
CHF 3.33
7D
0.9%
1Y
-4.3%
Basilea Pharmaceutica
Market Cap: CHF 549.0m
Engages in the discovering, developing, and commercializing drugs for bacterial or fungal infections.
BSLN
CHF 44.75
7D
-1.1%
1Y
4.3%
Cosmo Pharmaceuticals
Market Cap: CHF 885.6m
Focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.
COPN
CHF 55.30
7D
1.8%
1Y
-22.1%
Relief Therapeutics Holding
Market Cap: CHF 32.7m
A biopharmaceutical company, engages in identification, development, and commercialization of novel, patent protected products for the treatment of dermatological, metabolic, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally.
RLF
CHF 2.60
7D
21.8%
1Y
100.8%
Tecan Group
Market Cap: CHF 2.1b
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.
TECN
CHF 167.70
7D
-1.9%
1Y
-46.9%
SKAN Group
Market Cap: CHF 1.6b
Provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally.
SKAN
CHF 71.50
7D
-2.7%
1Y
-9.5%
Addex Therapeutics
Market Cap: CHF 5.6m
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland.
ADXN
CHF 0.057
7D
-0.7%
1Y
-14.2%
Lonza Group
Market Cap: CHF 39.6b
Supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.
LONN
CHF 561.20
7D
-0.6%
1Y
16.3%
Dottikon ES Holding
Market Cap: CHF 3.6b
Manufactures and sells performance chemicals, intermediates, and active pharmaceutical ingredients for the chemical, biotech, and pharmaceutical industries worldwide.
DESN
CHF 261.00
7D
23.7%
1Y
-0.8%
PolyPeptide Group
Market Cap: CHF 671.5m
Operates as a contract development and manufacturing company in Europe, the United States, and India.
PPGN
CHF 20.35
7D
8.7%
1Y
-35.6%
Roche Holding
Market Cap: CHF 208.8b
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.
ROG
CHF 260.20
7D
-0.9%
1Y
13.3%
Santhera Pharmaceuticals Holding
Market Cap: CHF 161.9m
A specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia.
SANN
CHF 12.58
7D
-0.5%
1Y
28.6%
Siegfried Holding
Market Cap: CHF 4.3b
Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.
SFZN
CHF 98.10
7D
2.3%
1Y
12.0%